SIRT1 suppresses human T-cell leukemia virus type 1 transcription

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8623-8631

  Tang, Hei Man Vincent ^a   Gao, Wei Wei ^a   Chan, Chi Ping ^a   Cheng, Yun ^a   Deng, Jian Jun ^a   Yuen, Kit San ^a   Iha, Hidekatsu ^b   Jin, Dong Yan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CRTC1 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; HYDROLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; RESVERATROL; SIRTUIN 1; SIRTUIN 1 DEACETYLASE; TAX PROTEIN; UNCLASSIFIED DRUG; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG POTENCY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN T-LYMPHOTROPIC VIRUS 1; JURKAT CELL LINE; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; T LYMPHOCYTE; TRANSCRIPTION REGULATION; VIRION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; ANTAGONISTS AND INHIBITORS; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

HUMAN T-LYMPHOTROPIC VIRUS 1;

CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, VIRAL; HEK293 CELLS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; JURKAT CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIRTUIN 1; STILBENES; TERMINAL REPEAT SEQUENCES; VIRION;

EID: 84938150491     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01229-15     Document Type: Article

References (50)

1. Matsuoka M, Jeang KT. 2011. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax,HBZand therapy. Oncogene 30:1379-1389. http://dx.doi.org/10.1038/onc.2010.537.
2. Watanabe T. 1997. HTLV-1-associated diseases. Int J Hematol 66:257-278. http://dx.doi.org/10.1016/S0925-5710(97)00077-7.
3. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K. 2010. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116: 1211-1219. http://dx.doi.org/10.1182/blood-2009-12-257410.
4. Zhao LJ, Giam CZ. 1992. Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21-base-pair repeats by protein-protein interaction. Proc Natl Acad SciUSA89:7070-7074. http://dx.doi.org/10.1073/pnas.89.15.7070.
5. Semmes OJ, Jeang KT. 1995. Definition of a minimal activation domain in human T-cell leukemia virus type I Tax. J Virol 69:1827-1833.
6. Kashanchi F, Brady JN. 2005. Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene 24:5938-5951. http://dx.doi.org/10.1038/sj.onc.1208973.
7. Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, Willems L. 2008. The HTLV-1 Tax interactome. Retrovirology 5:76. http://dx.doi.org/10.1186/1742-4690-5-76.
8. Simonis N, Rual JF, Lemmens I, Boxus M, Hirozane-Kishikawa T, Gatot JS, Dricot A, Hao T, Vertommen D, Legros S, Daakour S, Klitgord N, Martin M, Willaert JF, Dequiedt F, Navratil V, Cusick ME, Burny A, Van Lint C, Hill DE, Tavernier J, Kettmann R, Vidal M, Twizere JC. 2012. Host-pathogen interactome mapping for HTLV-1 and-2 retroviruses. Retrovirology 9:26. http://dx.doi.org/10.1186/1742-4690-9-26.
9. Sun SC, Yamaoka S. 2005. Activation of NF-κB by HTLV-I and implications for cell transformation. Oncogene 24:5952-5964. http://dx.doi.org/10.1038/sj.onc.1208969.
10. Matsuoka M, Green PL. 2009. The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology 6:71. http://dx.doi.org/10.1186/1742-4690-6-71.
11. Grassmann R, Aboud M, Jeang KT. 2005. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24:5976-5985. http://dx.doi.org/10.1038/sj.onc.1208978.
12. Ma G, Yasunaga J, Akari H, Matsuoka M. 2015. TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax. Proc Natl Acad SciU S A 112:2216-2221. http://dx.doi.org/10.1073/pnas.1419198112.
13. Koga H, Ohshima T, Shimotohno K. 2004. Enhanced activation of Tax-dependent transcription of human T-cell leukemia virus type I (HTLV-I) long terminal repeat by TORC3. J Biol Chem 279:52978-52983. http://dx.doi.org/10.1074/jbc.M409021200.
14. Siu YT, Chin KT, Siu KL, Choy EYW, Jeang KT, Jin DY. 2006. TORC1 and TORC2 coactivators are required for Tax activation of the human T-cell leukemia virus type 1 long terminal repeats. J Virol 80:7052-7059. http://dx.doi.org/10.1128/JVI.00103-06.
15. Jiang S, Inada T, Tanaka M, Furuta RA, Shingu K, Fujisawa J. 2009. Involvement of TORC2, a CREB co-activator, in the in vivo-specific transcriptional control of HTLV-1. Retrovirology 6:73. http://dx.doi.org/10.1186/1742-4690-6-73.
16. Chan CP, Siu YT, Kok KH, Ching YP, Tang HMV, Jin DY. 2013. Group I p21-activated kinases facilitate Tax-mediated transcriptional activation of the human T-cell leukemia virus type 1 long terminal repeats. Retrovirology 10:47. http://dx.doi.org/10.1186/1742-4690-10-47.
17. Tang HM, Gao WW, Chan CP, Siu YT, Wong CM, Kok KH, Ching YP, Takemori H, Jin DY. 2013. LKB1 tumor suppressor and salt-inducible kinases negatively regulate human T-cell leukemia virus type 1 transcription. Retrovirology 10:40. http://dx.doi.org/10.1186/1742-4690-10-40.
18. Haigis MC, Sinclair DA. 2010. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5:253-295. http://dx.doi.org/10.1146/annurev.pathol.4.110807.092250.
19. Guarente L. 2013. Calorie restriction and sirtuins revisited. Genes Dev 27:2072-2085. http://dx.doi.org/10.1101/gad.227439.113.
20. Chang HC, Guarente L. 2014. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 25:138-145. http://dx.doi.org/10.1016/j.tem.2013.12.001.
21. Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K, Schenk S, Milne J, Meyers DJ, Cole P, Yates J, III, Olefsky J, Guarente L, Montminy M. 2008. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456:269-273. http://dx.doi.org/10.1038/nature07349.
22. Qiang L, Lin HV, Kim-Muller JY, Welch CL, Gu W, Accili D. 2011. Proatherogenic abnormalities of lipid metabolism in SIRT1 transgenic mice are mediated through CREB deacetylation. Cell Metab 14:758-767. http://dx.doi.org/10.1016/j.cmet.2011.10.007.
23. Monteserin-Garcia J, Al-Massadi O, Seoane LM, Alvarez CV, Shan B, Stalla J, Paez-Pereda M, Casanueva FF, Stalla GK, Theodoropoulou M. 2013. Sirt1 inhibits the transcription factor CREB to regulate pituitary growth hormone synthesis. FASEB J 27:1561-1571. http://dx.doi.org/10.1096/fj.12-220129.
24. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, Schnolzer M, McBurney MW, Marmorstein R, Greene WC, Ott M. 2008. HIV-1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3:158-167. http://dx.doi.org/10.1016/j.chom.2008.02.002.
25. Hubbard BP, Sinclair DA. 2014. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 35: 146-154. http://dx.doi.org/10.1016/j.tips.2013.12.004.
26. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342. http://dx.doi.org/10.1038/nature05354.
27. Lee CW, Wong LLY, Tse EYT, Liu HF, Leong VYL, Lee JMF, Hardie DG, Ng IOL, Ching YP. 2012. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res 72:4394-4404. http://dx.doi.org/10.1158/0008-5472.CAN-12-0429.
28. Ching YP, Chun AC, Chin KT, Zhang ZQ, Jeang KT, Jin DY. 2004. Specific TATAA and bZIP requirements suggest that HTLV-I Tax has transcriptional activity subsequent to the assembly of an initiation complex. Retrovirology 1:18. http://dx.doi.org/10.1186/1742-4690-1-18.
29. Ching YP, Chan SF, Jeang KT, Jin DY. 2006. Retroviral oncoprotein Tax targets coiled-coil centrosomal protein TAX1BP2 to induce centrosome overduplication. Nat Cell Biol 8:717-724. http://dx.doi.org/10.1038/ncb1432.
30. Tang HMV, Pan K, Kong KYE, Hu L, Chan LC, Siu KL, Sun H, Wong CM, Jin DY. 2015. Loss of APD1 in yeast confers hydroxyurea sensitivity suppressed by Yap1p transcription factor. Sci Rep 5:7897. http://dx.doi.org/10.1038/srep07897.
31. Siu KL, Yeung ML, Kok KH, Yuen KS, Kew C, Lui PY, Chan CP, Tse H, Woo PCY, Yuen KY, Jin DY. 2014. Middle East respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in innate antiviral response. J Virol 88:4866-4876. http://dx.doi.org/10.1128/JVI.03649-13.
32. Siu KL, Chan CP, Woo PCY, Jin DY. 2014. Comparative analysis of the activation of unfolded protein response by spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus HKU1. Cell Biosci 4:3. http://dx.doi.org/10.1186/2045-3701-4-3.
33. Siu KL, Chan CP, Kok KH, Woo PCY, Jin DY. 2014. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirusMprotein is mediated through the first transmembrane domain. Cell Mol Immunol 11:141-149. http://dx.doi.org/10.1038/cmi.2013.61.
34. Chin KT, Zhou HJ, Wong CM, Lee JM, Chan CP, Qiang BQ, Yuan JG, Ng IOL, Jin DY. 2005. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res 33:1859-1873. http://dx.doi.org/10.1093/nar/gki332.
35. Tang HMV, Gao WW, Chan CP, Cheng Y, Chaudhary V, Deng JJ, Yuen KS, Wong CM, Ng IOL, Kok KH, Zhou J, Jin DY. 2014. Requirement of CRTC1 coactivator for hepatitis B virus transcription. Nucleic Acids Res 42:12455-12468. http://dx.doi.org/10.1093/nar/gku925.
36. +-dependent deacetylases (sirtuins). Biochim Biophys Acta 1799:726-739. http://dx.doi.org/10.1016/j.bbagrm.2010.06.003.
37. Yuen KS, Chan CP, Wong NH, Ho CH, Ho TH, Lei T, Deng W, Tsao SW, Chen H, Kok KH, Jin DY. 2015. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J Gen Virol 96:626-636. http://dx.doi.org/10.1099/jgv.0.000012.
38. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. 2004. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-2380. http://dx.doi.org/10.1038/sj.emboj.7600244.
39. Lodewick J, Lamsoul I, Polania A, Lebrun S, Burny A, Ratner L, Bex F. 2009. Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-κB pathway. Virology 386:68-78. http://dx.doi.org/10.1016/j.virol.2008.12.043.
40. Lodewick J, Sampaio C, Boxus M, Rinaldi AS, Coulonval K, Willems L, Roger PP, Bex F. 2013. Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model. Retrovirology 10:75. http://dx.doi.org/10.1186/1742-4690-10-75.
41. Siu YT, Jin DY. 2007. CREB-a real culprit in oncogenesis. FEBS J 274: 3224-3232. http://dx.doi.org/10.1111/j.1742-4658.2007.05884.x.
42. Altarejos JY, Montminy M. 2011. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 12: 141-151. http://dx.doi.org/10.1038/nrm3072.
43. Ravnskjaer K, Kester H, Liu Y, Zhang X, Lee D, Yates JR, III, Montminy M. 2007. Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J 26:2880-2889. http://dx.doi.org/10.1038/sj.emboj.7601715.
44. Wu H, Li T, Zeng M, Peng T. 2012. Herpes simplex virus type 1 infection activates the Epstein-Barr virus replicative cycle via a CREB-dependent mechanism. Cell Microbiol 14:546-559. http://dx.doi.org/10.1111/j.1462-5822.2011.01740.x.
45. Kim BK, Lim SO, Park YG. 2008. Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication. Hepatology 48:361-373. http://dx.doi.org/10.1002/hep.22359.
46. Fields PA, Taylor GP. 2012. "Antivirals" in the treatment of adult T cell leukaemia-lymphoma (ATLL). Curr Hematol Malig Rep 7:267-275. http://dx.doi.org/10.1007/s11899-012-0139-9.
47. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716. http://dx.doi.org/10.1038/nature06261.
48. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA. 2012. SIRT1 is required forAMPKactivation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675-690. http://dx.doi.org/10.1016/j.cmet.2012.04.003.
49. Banerjee P, Tripp A, Lairmore MD, Crawford L, Sieburg M, Ramos JC, Harrington W, Jr, Beilke MA, Feuer G. 2010. Adult T-cell leukemia/ lymphoma development in HTLV-1-infected humanized SCID mice. Blood 115:2640-2648. http://dx.doi.org/10.1182/blood-2009-10-246959.
50. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JEESY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA. 2013. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339:1216-1219. http://dx.doi.org/10.1126/science.1231097.